English MDX-1097 Cited by user 161.8.226.169 on 26 Mar 2024 MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy that has most recently been assessed in a Phase IIb clinical trial (2023) in…